

Legal Disclaimer

This presentation contains general information about the activities of Oneview Healthcare PLC (ABRN 610 611 768) (Oneview or Company) which is current as at 13 August 2025. It is in summary form and does not purport to be complete. It presents financial information on a statutory basis, prepared in accordance with International Financial Reporting Standards (IFRS), as well as information provided on a non-IFRS basis. This presentation is not a recommendation or advice in relation to Oneview or any product or service offered by Oneview. It is not intended to be relied upon as advice to investors or potential investors and does not contain all information relevant or necessary for an investment decision. It should be read in conjunction with Oneview's other periodic and continuous disclosure announcements filed with the Australian Securities Exchange and in particular the Half Year Results for the period ended to 30 June 2025. These are also available at www.oneviewhealthcare.com.

No representation or warranty, expressed or implied, is made as to the accuracy, adequacy or reliability of any statements, estimates or opinions or other information contained in this presentation. To the maximum extent permitted by law, Oneview, its subsidiaries and their respective directors, officers, employees and agents disclaim all liability and responsibility for any direct or indirect loss or damage which may be suffered by any recipient through use of or reliance on anything contained in or omitted from this presentation. No recommendation is made as to how investors should make an investment decision. Investors must rely on their own examination of Oneview, including the merits and risks involved. Investors should consult with their own professional advisors in connection with any acquisition of securities.

The information in this presentation is for general information only. To the extent that certain statements contained in this presentation may constitute "forward-looking statements" or statements about "future matters", the information reflects Oneview's intent, belief, or expectations at the date of this presentation. Subject to any continuing obligations under applicable law or any relevant listing rules of the Australian Securities Exchange, Oneview disclaims any obligation or undertakings to disseminate any updates or revisions to this information over time. Any forward-looking statements, including projections, guidance on future revenues, earnings and estimates, are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Oneview's actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. Any forward-looking statements, opinions and estimates in this presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions. For example, the factors that are likely to affect the results of Oneview include, but are not limited to, general economic conditions in any of the territories in which Oneview operates, exchange rates, competition in the markets in which Oneview will operate and the inherent regulatory risks in the business of Oneview. Neither Oneview, nor any other person, gives any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this presentation will actually occur. In addition, please note that past performance is no guarantee or indication of future performance.

This presentation does not constitute an offer to issue or sell, or solicitation of an offer to buy, any securities or other financial products in any jurisdiction. The distribution of this presentation outside Australia may be restricted by law. Any recipient of this presentation outside Australia must seek advice on and observe any such restrictions. This presentation may not be reproduced or published, in whole or in part, for any purpose without the prior written permission of Oneview.

All amounts are in Euros unless otherwise specified. All references starting with FY refer to the year ended 31st December 2024. H1 refers to the period ended 30 June 2025 (H1 25).



Oneview Healthcare plc (ASX: ONE)

Healthcare technology company enabling the Connected Care Experience in hospitals and healthcare systems with a modular, scalable software platform that connects the patient room to the care team and the hospitals' technology systems, delivering efficiencies for the hospital and a better, more engaged care experience for patients

Founded in 2008 in Dublin, Ireland

ISO 27001, 27701 & 42001

Our Mission

To improve connected care experiences, every day

Our Vision

Redefining the digital environment of care to make it accessible, seamless and reliable for all

Our US footprint includes 3 hospitals that have been recognised in the top 20 nationwide *



Speakers



James Fitter Chief Executive Officer



Darragh Lyons Chief Financial Officer

Contents

1) H1 2025 in Review 2) H1 2025 Financial Results Overview

3) Reimagining the Patient Experience with AI

4) Commercial & Sales Updates

5) Deployment Updates

6) Outlook

7) Q&A





H1 2025 in Review

H12025 Results

H12025

Revenue

€6.3m

(A\$10.9m)

Up 36%

Recurring Revenue

€3.8m

(A\$6.5m)

 \uparrow

Up 7%

Gross Margin

61%

(2024: 73%)

 \downarrow

Down 12%

Operating EBITDA

Loss

€4.5m (A\$7.7m)

 \uparrow

Up 21%

As at 30 June 2025

Cash

€8.2m



(31 December 2024:

(A\$14.7m)

€13.8)

2 new customer logos added



Live Endpoints


13,526

Up (net) 1% in H1 25

Recurring Revenue per live endpoint per day

€1.54


Up 5% in H1 2025



First initiative from Oneview's AI Strategy was launched during H1 2025: Ovie, a Gen AI-powered Care Assistant



36% YoY Revenue Growth























A MEMBER OF THE MONTEFIORE HEALTH SYSTEM



ASX: ONE Investment Highlights



Efficiency

- Progressing towards faster and more efficient deployments
- Embedding AI-powered solutions into every business function, yielding measurable performance improvements
- Restructured our Australian and other functional teams to align operations with current business opportunities and strategic priorities



Execution

-) 2 new customer logos added during H1 2025
- Sales pipeline expanding and maturing with several late-stage pipeline opportunities
- Three-year contract extension secured with a key strategic customer, driving over 20% year-onyear growth in annual recurring revenue from this customer



- Developing a new User Experience which will be delivered during H2 2025
- Developing Al-powered patient engagement products having built a solid Al foundation
- Achieved ISO 42001 certification, becoming one of the first companies on the ASX and in the connected care sector to attain this certification for its AI Management System





H12025 Financial Performance

36% growth in **revenue**

7% growth in recurring revenue

H1 2025 Gross Margin of **61%** (H1 2024: 73%) impacted by revenue mix (i.e. greater proportion of deployment revenue)

Restructured our global operations to better align Australian and functional operations with current strategic priorities

- ~10% reduction in global employee headcount
- continued focus on improving business efficiency

Operating EBITDA¹ loss of **€4.5 million** impacted by:

- Restructuring charges of €168k and;
- Previous investment in resources to support expected deployment activity from the Baxter and direct sales pipelines

	Period ended 30 June 2025	Period ended 30 June 2024	Variance
	€'m	€'m	%
Recurring revenue	3.8	3.6	7%
Non-recurring revenue	2.5	1.1	132%
Total Revenue	6.3	4.7	36%
Cost of sales	(2.5)	(1.3)	97%
Gross Profit	3.8	3.4	13%
Cash operating expenses	(8.3)	(7.1)	17%
Operating EBITDA loss	(4.5)	(3.7)	21%
Non-cash expenses:			
Share based payment expense	(1.6)	(1.7)	-3%
Depreciation & amortisation	(0.3)	(0.3)	3%
Net finance income / (costs)	(1.5)	0.1	-
Loss before tax	(7.9)	(5.5)	44%
Income tax expense	-	-	-
Loss after tax	(7.9)	(5.5)	44%

¹ Operating EBITDA excludes deprecation, amortisation, finance & FX charges / gains and non-cash share based payment charges



Financial Position as at 30 June 2025

Balance Sheet Position	As at 30 June 2025	As at 31 December 2024	Variance
	€'m	€'m	%
Cash and cash equivalents	8.2	13.8	-41%
Trade & other receivables	3.1	5.3	-42%
Inventory	2.6	3.1	-17%
Other assets	2.3	3.8	-39%
Total Assets	16.1	26.0	-38%
Trade and other payables	0.7	1.3	-46%
Deferred income	2.9	5.0	-42%
Accruals and other liabilities	5.1	6.4	-21%
Total Liabilities	8.6	12.7	-32%
Net Assets / Total Equity	7.5	13.3	-44%

Cash Flow Statement Summary	H1 2025	H1 2024	Variance
	€'m	€'m	%
Net cash used in operating activities	(4.8)	(5.2)	-8%
Net cash used in investing activities	-	(0.3)	-100%
Net cash generated by / (used in) financing activities	(0.2)	(0.1)	180%
Net decrease in cash held	(5.1)	(5.6)	-10%
Cash as at 1 January	13.8	11.5	20%
Foreign exchange impact on cash	(0.6)	0.1	n/a
Cash as at 30 June	8.2	6.0	37%

€8.2 million of Cash as at 30 June 2025

Lower cash burn in H1 2025 compared to H1 2024 driven by higher cash receipts, aligned with H1 2025 revenue

Restructuring executed in June 2025 reduced global headcount by ~10% and will deliver annual cost-savings of €1.1m

Strong inventory of our proprietary deployment hardware held in the US shields us from the current tariff and trading volatility

€1.5 million of debtors as at 30 June 2025 compared to €3.3 million at 31 December 2024





Al-Driven Patient Engagement





Faster speed to value and revenue



What we build: Al-powered products

- Personalize engagement and experience to each patient's needs
- Monitors behavior and environment to surface realtime insights
- Anticipates needs and risks to guide timely staff action
- Orchestrates workflows to optimize efficiency



How we work: Al-powered delivery and operations

- Al Communities of Practice to share knowledge and skills across our teams
- Al-powered product research and prototyping
- Reimagined Software Development Lifecycle using AI Agents to accelerate software delivery



Our Al foundation: safe, responsible, capable


Al Management System •

Evaluation & Monitoring •

- **Executive & Staff Upskilling**
- Only ASX listed company
- **Regulatory Compliance**
- to date to be ISO 42001 certified



Al Augmented Software Development Lifecycle



Ovie ... Oneview's Al-Driven Ecosystem



Ovie, your virtual care team member

intelligence engine powering personalization, anticipation, orchestration, and context-awareness across the Oneview platform

Patient Centric



Ovie Engage

context-aware widget surfacing what's important for patients



Ovie Voice

enables natural, conversational interaction with Ovie



Care Team Centric

Ovie Console

real-time dashboard surfacing what's important for staff



Ovie Rounds

focused, context-aware rounding for staff and leaders





Al-augmented hybrid care

Ensuring patients receive appropriate & timely care

Or personal Availability ШHigher

Virtual Care

- Complex education
- Virtual care workflows (e.g. meds to beds, admission/discharge, case management, dual sign-off)
- "At-the-elbow" support

Floor Nurse

- Urgent care
- Physical care
- Personalized connection

communication

Lower

Ovie Al

Comfort needs

• Basic education

Multi-lingual

Common guestions

Basic data collection

Cost


Higher




Innovation Update


Patient Centric








Care Team Centric















vie Voice

Al-Powered Insights

Identification of Patient Groups


Behavioural clustering techniques uncover distinct groups of patients by analysing demographic characteristics, visit information and system utilization

Personalised Interventions

Insights from clustering enable the design of tailored optimizations to maximise system utilization and customer value

Anticipating Issues

Working with an innovation customer in the US to determine if Oneview behavioural data correlates to HCAHPS satisfaction data







Our Global Footprint


Oneview customers in Australia, Thailand, Ireland and the US


Focused on US market to drive near-term significant growth aspirations, with opportunistic expansions in other regions

Proven ability to target other markets and opportunities in the future



US Customers





Commercial Strategy

- Adding new logos is obviously our key commercial focus
- Once new customers are "landed", we are able to demonstrate our products value and scalability in the customers production environment

Annual recurring revenue (software subs)



Examples of our deployment expansions with enterprise customers

Customer D

Customer B

Customer A

D

1500

1500

3000

4500

Very 'sticky' customers: low customer churn



Bilateral expansion:

- * 92% product upsell
- * enterprise-wide expansion




New Customer Logos

Strong momentum in the sales pipeline positions us to land new customer logos in H2 2025

Several new logos in contract negotiations








Baxter Partnership

Momentum is building as opportunities work their way through the funnel
















Baxter Partnership Potential





The Connected Care Experience


We have evolved from a single platform solution to a suite of revenue-generating products and delivery channels

Modular & Scalable:

- √ 92% upsell opportunity with existing Care Experience customers
- Products can be sold as standalone

Management will track and report on endpoints (rather than beds) going forward

MyStay Patient Devices



Digital Whiteboard




Digital Door Sign





Live Endpoints

Dec '25



> 20,000 Contracted Endpoints

Note:

894 endpoints decommissioned in June 2025 with Australian customer due to budgetary constraints offset by materially higher margin deployments in the U.S.



Live Endpoints

Average recurring revenue per new endpoint installed was 96% higher than the endpoints decommissioned

This will represent an incremental ~€0.3 million in annual recurring revenue from H2 2025+

Annualised recurring revenue per endpoint

(based on live endpoints at the end of the period):

2024

€1.47

H1 2025

€1.54



5% Growth (despite weakening USD in Q2)



Our Path to More Efficient Deployments Continues

H1 & H2 2025

Investing in configuration tooling

- to reduce project implementation times
- reduce on-going support overheads and costs
- enabling partners to install and operate the system

Infrastructure automation with AI Agents

- optimisation of deployment pipelines
- optimisation of infrastructure-as-code
- continuation of migration to containers

Exploration of Algenerated configuration

for complex feature configuration

H₂ 2025

Targeting 90-day deployments

- overhaul the deployment methodology
- get beds live faster
- accelerate commencement of recurring revenue
- reduce and remove inefficiencies
- standardise the configuration of the platform





ONE H1 2025 Outlook





Performance

36% increase in Revenue during H1 2025 (compared to H1 2024)

7% increase in recurring revenue

5% increase in revenue per endpoint



Pipeline

- Record US sales opportunity pipeline comprised of potential direct sales and sales under the Baxter VAR partnership
- Several additional logos in contract negotiation



Products

- New user experience will be delivered in H2 2025
- Developing Al-powered products; launched Ovie a Gen Al-powered Care Assistant
- Achieved ISO 42001 certification for its Al Management System



Productivity

- Restructured operations to align with strategic priorities
- Continued focus on operating more efficiently
- Early efficiency gains from the adoption of Alpowered tools across the business
- Progressing towards more efficient deployments



Thank You





Oneview / the connected care experience company

A&P